Stryker Corporation $SYK Stock Position Lifted by Amundi

Amundi grew its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 18.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,246,353 shares of the medical technology company's stock after purchasing an additional 192,447 shares during the period. Amundi owned approximately 0.32% of Stryker worth $392,402,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Sankala Group LLC bought a new stake in shares of Stryker during the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker during the fourth quarter worth approximately $27,000. Finally, Gables Capital Management Inc. acquired a new stake in Stryker in the second quarter worth approximately $25,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of the business's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda Stryker sold 300,000 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares of the company's stock, valued at $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Trading Down 0.1%

Stryker stock opened at $302.92 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a market cap of $116.19 billion, a price-to-earnings ratio of 31.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.37. The firm's 50 day moving average price is $328.30 and its two-hundred day moving average price is $329.01.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Citizens Jmp decreased their price target on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research note on Monday, August 3rd. Citigroup reissued a "buy" rating on shares of Stryker in a research note on Thursday, August 13th. BTIG Research cut their price objective on Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a report on Friday, July 31st. UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They set a "buy" rating and a $400.00 target price for the company. Finally, Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.